Zhipeng Su
Impact in
- Cancer Research top 10%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- Pituitary Gland Disorders and Treatments
Papers in
-
- RNA Research and Splicing 5
- Glycosylation and Glycoproteins Research 4
-
- Pituitary Gland Disorders and Treatments 14
- Co-authors
- Kevin D. Burns (1 shared paper)Chengde Wang (20 shared papers)Lin Cai (17 shared papers)Weiming Zheng (18 shared papers)Qun Li (18 shared papers)Fansheng Kong (5 shared papers)Jianglong Lu (19 shared papers)Zhe Wu (14 shared papers)
- Journals
- Molecular and Cellular Endocrinology (3 papers)International Immunopharmacology (2 papers)Frontiers in Oncology (2 papers)Cancer Cell International (2 papers)PLoS ONE (2 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Zhipeng Su
76 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 114
- Cancer Research 229
- Endocrinology, Diabetes and Metabolism 186
- Genetics 110
- Immunology 201
- Molecular Biology 588
Countries citing papers authored by Zhipeng Su
This map shows the geographic impact of Zhipeng Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhipeng Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhipeng Su more than expected).
Fields of papers citing papers by Zhipeng Su
This network shows the impact of papers produced by Zhipeng Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhipeng Su. The network helps show where Zhipeng Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Zhipeng Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 78 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2006 | 170 | |
| 2 | 2018 | 113 | |
| 3 | 2020 | 77 | |
| 4 | 2013 | 71 | |
| 5 | 2020 | 51 | |
| 6 | Temozolomide promotes immune escape of GBM cells via upregulating PD-L1. | 2019 | 47 |
| 7 | 2023 | 39 | |
| 8 | 2017 | 38 | |
| 9 | 2015 | 34 | |
| 10 | 2020 | 32 | |
| 11 | 2017 | 29 | |
| 12 | 2018 | 29 | |
| 13 | 2017 | 27 | |
| 14 | 2020 | 27 | |
| 15 | 2021 | 25 | |
| 16 | 2018 | 21 | |
| 17 | 2018 | 20 | |
| 18 | 2018 | 20 | |
| 19 | 2015 | 19 | |
| 20 | 2018 | 18 |
About Zhipeng Su
Zhipeng Su is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism, Immunology, Cancer Research and Genetics, having authored 78 papers that have together received 1.4k indexed citations. Recurring topics across this work include Pituitary Gland Disorders and Treatments (14 papers), Glioma Diagnosis and Treatment (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), RNA Research and Splicing (5 papers), Glycosylation and Glycoproteins Research (4 papers), Neuroblastoma Research and Treatments (4 papers), Adrenal and Paraganglionic Tumors (4 papers) and Cancer-related molecular mechanisms research (4 papers). The work is most often cited by research in Cancer Research (229 citations), Endocrinology, Diabetes and Metabolism (186 citations), Genetics (110 citations), Immunology (201 citations) and Molecular Biology (588 citations). Zhipeng Su has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Kevin D. Burns, Chengde Wang, Lin Cai, Weiming Zheng, Qun Li, Fansheng Kong, Jianglong Lu, Zhe Wu, Siyan Chen and Liang Feng. Their work appears in journals such as Molecular and Cellular Endocrinology, International Immunopharmacology, Frontiers in Oncology, Cancer Cell International and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.